Leukemia, Myelomonocytic, Juvenile
"Leukemia, Myelomonocytic, Juvenile" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
MeSH Number(s)
C04.557.337.539.525
C15.378.190.615.520
Concept/Terms
Leukemia, Myelomonocytic, Juvenile- Leukemia, Myelomonocytic, Juvenile
- Juvenile Myelomonocytic Leukemia
- Juvenile Myelomonocytic Leukemias
- Leukemia, Juvenile Myelomonocytic
- Leukemias, Juvenile Myelomonocytic
- Myelomonocytic Leukemia, Juvenile
- Myelomonocytic Leukemias, Juvenile
- Juvenile Chronic Myelogenous Leukemia
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myelomonocytic, Juvenile".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myelomonocytic, Juvenile".
This graph shows the total number of publications written about "Leukemia, Myelomonocytic, Juvenile" by people in Harvard Catalyst Profiles by year, and whether "Leukemia, Myelomonocytic, Juvenile" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 3 | 0 | 3 |
| 2023 | 1 | 0 | 1 |
Below are the most recent publications written about "Leukemia, Myelomonocytic, Juvenile" by people in Profiles.
-
Long-term proliferation of immature hypoxia-dependent JMML cells supported by a 3D in vitro system. Blood Adv. 2023 04 25; 7(8):1513-1524.
-
Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes. Blood Cancer Discov. 2022 11 02; 3(6):536-553.
-
Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects. Elife. 2022 05 10; 11.
-
Inhibition of BTK and PI3Kd impairs the development of human JMML stem and progenitor cells. Mol Ther. 2022 07 06; 30(7):2505-2521.
-
Implications of mosaicism in variant interpretation: A case of a de novo homozygous NF1 variant. Eur J Med Genet. 2021 Jul; 64(7):104236.
-
Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia. Blood Adv. 2020 07 28; 4(14):3246-3251.
-
Case 37-2019: A 20-Month-Old Boy with Severe Anemia. N Engl J Med. 2019 Nov 28; 381(22):2158-2167.
-
Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia. Br J Haematol. 2019 10; 187(2):163-173.
-
Panobinostat inhibits the proliferation of CD34+ CD38- cells under stimulation of hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia. Pediatr Blood Cancer. 2018 11; 65(11):e27261.
-
Juvenile myelomonocytic leukemia-associated variants are associated with neo-natal lethal Noonan syndrome. Eur J Hum Genet. 2017 04; 25(4):509-511.